Space Storable, Thrust-Vectorable Rocket Motor Nozzle and Related Methods

A thrust-vectoring rocket motor nozzle includes a forward assembly having a forward shell with a flange configured for connection to a motor and a throat portion opposite the flange. A ball joint sleeve may be disposed proximate the throat portion, and an exit cone assembly may include a ball joint socket configured to mate with the ball joint sleeve to allow movement of the exit cone assembly about one or more axes relative to the forward assembly. A thermal barrier may be disposed in a gap between the forward assembly and the exit cone assembly. The forward assembly may include a throat insulator mechanically locked within the forward shell. Related methods include forming thrust-vectorable rocket motor nozzles. Rocket motors may include such nozzles

Tolerability of oral sorafenib in pet dogs with a diagnosis of cancer

Amanda Foskett, Christina Manley, Rebecca Naramore, Ira K Gordon, Bridget M Stewart, Chand Khanna The Oncology Service, LLC, Leesburg, VA, USA Abstract: Sorafenib is a multi-target small molecule inhibitor of the RAF kinase family and VEGFR-2/PDGFR. The US Food and Drug Administration approved sorafenib in human patients with liver, thyroid, or renal carcinoma. The aim of this study was to help guide future pharmacokinetic (PK) studies of sorafenib in dogs with a cancer diagnosis. Client-owned dogs were eligible if they had a cytologic or histologic diagnosis of cancer. Patients were enrolled at escalating doses of sorafenib. Patients were evaluable for the study if they received at least one dose of sorafenib and presented 1 week later for a follow-up examination, blood work, and assessment of drug tolerability. The goal of this study was not to define a maximum tolerated dose as may be reasonable in conventional cytotoxic chemotherapy drugs, but rather to describe the tolerability of this drug in dogs with a cancer diagnosis, as a prequel to future sorafenib PK studies. No patients in the study had any evidence of adverse events that were attributable to sorafenib. Doses of 3 mg/kg were well tolerated and associated with a suggestion of clinical activity, supportive of future PK, and pharmacodynamic analysis. Such future studies are recommended at this dose to define the associated exposure achieved and determine a reasonable schedule for sorafenib administration. Keywords: sorafenib, cancer, tolerability study, developmental therapeutics&nbsp